At the news
? NEUTRALIMPACT 2/10 144 filed Nov 2, 2026 at 16:38 ET
Director George J. Morrow filed a Form 144 notice of intent to sell 14,700 shares of Neurocrine Biosciences common stock, with an approximate market value of $2.15 million based on the filing date. The shares are to be received upon exercise of stock options, and the sale is planned under a Rule 10b5-1 trading plan adopted on May 26, 2026.
- Director George J. Morrow filed Form 144 to sell 14,700 shares of Neurocrine Biosciences common stock.
- The approximate market value of the proposed sale is $2,147,670.
- Shares will be acquired upon exercise of stock options.
- The sale is planned under a Rule 10b5-1 trading plan adopted on May 26, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access